IQVIA’s (IQV) “Outperform” Rating Reiterated at William Blair

William Blair reissued their outperform rating on shares of IQVIA (NYSE:IQV) in a research report released on Wednesday morning,RTT News reports.

A number of other brokerages also recently issued reports on IQV. Evercore ISI reduced their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. The Goldman Sachs Group decreased their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. JPMorgan Chase & Co. cut their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. BTIG Research decreased their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, Morgan Stanley cut their price target on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Four analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $256.19.

IQVIA Trading Down 0.7 %

Shares of IQVIA stock opened at $199.06 on Wednesday. IQVIA has a 52-week low of $187.62 and a 52-week high of $261.73. The stock has a market cap of $36.13 billion, a PE ratio of 26.12, a PEG ratio of 2.07 and a beta of 1.49. The firm has a 50-day moving average of $212.24 and a 200-day moving average of $224.23. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

Institutional Investors Weigh In On IQVIA

A number of institutional investors have recently added to or reduced their stakes in the business. ORG Partners LLC raised its position in IQVIA by 2,376.2% during the 2nd quarter. ORG Partners LLC now owns 520 shares of the medical research company’s stock worth $108,000 after purchasing an additional 499 shares during the last quarter. Clear Harbor Asset Management LLC boosted its holdings in IQVIA by 17.9% in the second quarter. Clear Harbor Asset Management LLC now owns 3,919 shares of the medical research company’s stock valued at $829,000 after acquiring an additional 596 shares during the last quarter. Sawgrass Asset Management LLC bought a new position in IQVIA during the 2nd quarter worth approximately $11,874,000. Blue Trust Inc. lifted its position in shares of IQVIA by 702.9% in the 2nd quarter. Blue Trust Inc. now owns 281 shares of the medical research company’s stock worth $59,000 after purchasing an additional 246 shares during the period. Finally, Gradient Investments LLC increased its position in shares of IQVIA by 15.6% during the second quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock worth $9,600,000 after buying an additional 6,134 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.